Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for type 1 diabetes.

Nick Giannoukakis1, Massimo Trucco

  • 1Diabetes Institute, Pediatric Research Section, Children's Hospital of Pittsburgh and University of Pittsburgh, Rangos Research Center, Pittsburgh, PA 15213, USA.

American Journal of Therapeutics
|November 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal proteomics of leptin treatment in humans with acute and chronic energy deficiency-induced hypoleptinemia reveal novel, mainly immune-related, pleiotropic effects.

Metabolism: clinical and experimental·2024
Same author

Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approaches.

Frontiers in endocrinology·2023
Same author

Uncoupling hepatic insulin resistance - hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes.

Frontiers in endocrinology·2023
Same author

Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.

Frontiers in immunology·2023
Same author

Central tolerance promoted by cell chimerism.

Proceedings of the National Academy of Sciences of the United States of America·2022
Same author

Response to Comment on Pietropaolo et al. Incidence of an Insulin-Requiring Hyperglycemic Syndrome in SARS-CoV-2- Infected Young Individuals: Is It Type 1 Diabetes? Diabetes 2022;71:2656-2663.

Diabetes·2022
Same journal

Abrocitinib as a Novel Therapeutic Option for Elastolytic Giant Cell Granuloma: A Case Report.

American journal of therapeutics·2026
Same journal

Dupilumab for Lichen Amyloidosis in an Elderly Multimorbid Patient.

American journal of therapeutics·2026
Same journal

Deucravacitinib for Generalized Pustular Psoriasis and Comorbid Polymyositis: Dual Efficacy and Favorable Safety.

American journal of therapeutics·2026
Same journal

Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.

American journal of therapeutics·2026
Same journal

Do Not Treat a Sequencing Report: Therapeutic Stewardship in Endometrial Microbiome Testing.

American journal of therapeutics·2026
Same journal

Right Side Accessory Pathway Mediated Cardiomyopathy Treated with Amiodarone: First Adult Case Report.

American journal of therapeutics·2026
See all related articles

Gene and cell-based therapies show promise for treating type 1 diabetes mellitus (DM1) by addressing insulin deficiency and immune rejection. While successful in animal models, human efficacy for this complex autoimmune disorder requires further demonstration.

Area of Science:

  • Immunology
  • Endocrinology
  • Genetics

Background:

  • Type 1 diabetes mellitus (DM1) is a complex autoimmune disorder characterized by insulin deficiency.
  • Current treatments focus on insulin replacement, often via transplantation, which faces challenges due to immune rejection.
  • Gene and cell-based strategies are being explored to overcome these limitations.

Purpose of the Study:

  • To review gene and cell-based therapeutic and prophylactic interventions for type 1 diabetes mellitus.
  • To discuss the potential of these strategies in addressing insulin absence and immune responses.
  • To evaluate the progress and challenges in translating these approaches to human clinical application.

Main Methods:

  • Review of existing literature on gene and cell-based therapies for DM1.

Related Experiment Videos

  • Analysis of immunological and genetic factors contributing to DM1 pathogenesis.
  • Examination of strategies for insulin replacement and immune tolerance induction.

    • Main Results:

    • Gene and cell-based therapies are being investigated as alternatives to traditional immunosuppression for islet transplantation.
    • Understanding of DM1's cellular mechanisms has led to promising prophylactic approaches.
    • Early successes in animal models suggest potential, but human efficacy is yet to be proven.

    Conclusions:

    • Gene and cell-based interventions offer potential for type 1 diabetes mellitus treatment and prevention.
    • Overcoming antidonor immunoreactivity is a key challenge for transplantation-based therapies.
    • Further research is needed to validate the efficacy of these advanced strategies in human patients.